Predicting new molecular targets for known drugs

Nature

Volumn 462, Issue 7270, 2009, Pages 175-181

  Keiser, Michael J ^a,b   Setola, Vincent ^c   Irwin, John J ^a   Laggner, Christian ^a   Abbas, Atheir I ^d   Hufeisen, Sandra J ^e   Jensen, Niels H ^e   Kuijer, Michael B ^c   Matos, Roberto C ^c   Tran, Thuy B ^c   Whaley, Ryan ^c   Glennon, Richard A ^f   Hert, Jérme ^a   Thomas, Kelan L H ^a,g   Edwards, Douglas D ^a   Shoichet, Brian K ^a   Roth, Bryan L ^c,e  

^a Department of Pharmaceutical Chemistry ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Pharmacology

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; ALPHA 1 ADRENERGIC RECEPTOR; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR; BRINZOLAMIDE; DELAVIRDINE; DENOPAMINE; DIMETHOLIZINE; DIPHEMANIL METHYLSULFATE; DOMPERIDONE; EMILACE; FLUANISONE; FLUOXETINE; HISTAMINE H4 RECEPTOR; IFENPRODIL TARTRATE; INDORAMIN; LIGAND; LISURIDE; MEBHYDROLIN NAPADISILATE; N,N DIMETHYLTRYPTAMINE; NEUROLEPTIC AGENT; PAROXETINE; PERGOLIDE MESILATE; REVANIL; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TETRABENAZINE; UNCLASSIFIED DRUG;

AMMONIUM COMPOUND; CHEMICAL ANALYSIS; COMPARATIVE STUDY; DRUG DEVELOPMENT; INHIBITOR; LIGAND; RODENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG WITHDRAWAL; EMBRYO; EXPERIMENTAL STUDY; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SUDDEN DEATH; UNITED STATES;

ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LIGANDS; MICE; MICE, KNOCKOUT; OFF-LABEL USE; PHARMACEUTICAL PREPARATIONS; RECEPTORS, SEROTONIN; SUBSTRATE SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70449634957     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08506     Document Type: Article

References (53)

1. Ehrlich P.Thetheory andpractice ofchemotherapy. Folia Serologica7 697-714 (1911).
2. Peterson, R. T. Chemical biology and the limits of reductionism. Nature Chem. Biol. 4, 635-638 (2008).
3. Nobeli, I., Favia, A. D. & Thornton, J. M. Protein promiscuity and its implications for biotechnology. Nature Biotechnol. 27, 157-167 (2009).
4. Marona-Lewicka, D. & Nichols, D. E. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol. Biochem. Behav. 87, 453-461 (2007).
5. Marona-Lewicka, D. & Nichols, D. E. WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D4 receptor activation. Behav. Pharmacol. 20, 114-118 (2009).
6. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353-359 (2004).
7. Rix, U. et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063 (2007).
8. Hopkins, A. L. Network pharmacology. Nature Biotechnol. 25, 1110-1111 (2007).
9. Roth, B. L. Drugs and valvular heart disease. N. Engl. J. Med. 356, 6-9 (2007).
10. Bajorath, J. Computational analysis of ligand relationships within target families. Curr. Opin. Chem. Biol. 12, 352-358 (2008).
11. Oprea, T. I., Tropsha, A., Faulon, J. L. & Rintoul, M. D. Systems chemical biology. Nature Chem. Biol. 3, 447-450 (2007).
12. Newman, D. J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51, 2589-2599 (2008).
13. Siegel, M. G. & Vieth, M. Drugs in other drugs: a new look at drugs as fragments. Drug Discov. Today 12, 71-79 (2007).
14. Miller, J. R. et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl Acad. Sci. USA 106, 1737-1742 (2009).
15. Walsh, C. T. & Fischbach, M. A. Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery. Proc. Natl Acad. Sci. USA 106, 1689-1690 (2009).
16. Young, D. W. et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nature Chem. Biol. 4, 59-68 (2008).
17. Wagner, B. K. et al. Large-scale chemical dissection of mitochondrial function. Nature Biotechnol. 26, 343-351 (2008).
18. Krejsa, C. M. et al. Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Dev. 6, 470-480 (2003).
19. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
20. Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S. & Hopkins, A. L. Global mapping of pharmacological space. Nature Biotechnol. 24, 805-815 (2006).
21. Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nature Biotechnol. 25, 197-206 (2007).
22. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
23. Hert, J., Keiser, M. J., Irwin, J. J., Oprea, T. I. & Shoichet, B. K. Quantifying the relationships among drug classes. J. Chem. Inf. Model. 48, 755-765 (2008).
24. Nigsch, F., Bender, A., Jenkins, J. L. & Mitchell, J. B. Ligand-target prediction using Winnow and naive Bayesian algorithms and the implications of overall performance statistics. J. Chem. Inf. Model. 48, 2313-2325 (2008).
25. Schuffenhauer, A. et al. An ontology for pharmaceutical ligands and its application for in silico screening and library design. J. Chem. Inf. Comput. Sci. 42, 947-955 (2002).
26. Olah, M. et al. in Chemical Biology: From Small Molecules to Systems Biology and Drug Design (eds Schreiber, S. L., Kapoor, T. M. & Wess, G.) 760-786 (Wiley-VCH, 2007).
27. Lomasney, J. W. et al. Molecular cloning and expression of the cDNA for the a1A-adrenergic receptor. The gene for which is located on human chromosome 5. J. Biol. Chem. 266, 6365-6369 (1991).
28. Fontanilla, D. et al. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323, 934-937 (2009).
29. Su, T. P., Hayashi, T. & Vaupel, D. B. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci. Signal. 2, pe12 (2009).
30. Roth, B. L., Lopez, E., Patel, S. & Kroeze, W. K. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrasment of riches? Neuroscientist 6, 252-262 (2000).
31. Smith, R. L., Canton, H., Barrett, R. J. & Sanders-Bush, E. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol. Biochem. Behav. 61, 323-330 (1998).
32. Kohen, R. et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66, 47-56 (1996).
33. Pierce, P. A. & Peroutka, S. J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology (Berl.) 97, 118-122 (1989).
34. Abbas, A. I. et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J. Neurosci. 29, 7124-7136 (2009).
35. Kurland, A. A., Mc, C. K. & Michaux, W. W. Clinical trial of haloanisone (R-2028) with hospitalized psychiatric patients. J. New Drugs 2, 352-360 (1962).
36. Gankina, E. M. et al. Effect of some antihistamine preparations on binding of 3H-mepyramine and 3H-cimetidine to histamine receptors in rat brain. Pharm. Chem. J 26, 373-376 (1992).
37. Gankina, E. M. et al. The effect of antihistaminic preparations on the binding of labelled mepyramine, ketanserin and quinuclidinyl benzilate in the rat brain [in Russian with English abstract]. Eksp. Klin. Farmakol. 56, 22-24 (1993).
38. Heykants, J. et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet. 6, 61-70 (1981).
39. FDA. Talk Paper: FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production, http://www.fda.gov/Drugs/ DrugSafety/InformationbyDrugClass/ucm173886.htm. (7 June 2004).
40. Stork, D. et al. State dependent dissociation of HERG channel inhibitors. Br. J. Pharmacol. 151, 1368-1376 (2007).
41. Michelson, D. et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br. J. Psychiatry 176, 363-368 (2000).
42. Berger, M., Gray, J. A. & Roth, B. L. The extended pharmacology of serotonin. Annu. Rev. Med. 60, 355-366 (2009).
43. Waldinger, M. D., Hengeveld, M. W., Zwinderman, A. H. & Olivier, B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J. Clin. Psychopharmacol. 18, 274-281 (1998).
44. Peters, J. U., Schnider, P., Mattei, P. & Kansy, M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 4, 680-686 (2009).
45. Scott, L. J. & Perry, C. M. Delavirdine: a review of its use in HIV infection. Drugs 60, 1411-1444 (2000).
46. Dijkstra, D. et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J. Invest. Dermatol. 128, 1696-1703 (2008).
47. Mehvar, R., Jamali, F., Watson, M. W. & Skelton, D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab. Dispos. 15, 250-255 (1987).
48. Masanori, I., Tetsuya, T., Tomihiro, I., Taku, N. & Shigeyuki, T. b1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase. Biochem. Pharmacol. 36, 1947-1954 (1987).
49. Jensen, N. H. et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 2303-2312 (2008).
50. Irwin, J. J. & Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182 (2005).
51. James, C., Weininger, D. & Delany, J. Daylight Theory Manual (Daylight Chemical Information Systems Inc., 1992-2005).
52. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
53. Roth, B. L. et al. Salvinorin A: a potent naturally occurring nonnitrogenous k opioid selective agonist. Proc. Natl Acad. Sci. USA 99, 11934-11939 (2002).